Health

Telix Announces A$600 Million Convertible Bonds Offering

MELBOURNE, Australia, July 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX) (Telix, the Company, the Issuer) today launches an offering ofA$600 million of convertible notes due 2029 (the Offering). The convertible notes, also referred to as "convertible bonds" (Convertible Bonds)...

2024-07-23 16:35 1741

SND Introduces Revolutionary Moderated Drinking Treatment Program

TOKYO, July 23, 2024 /PRNewswire/ -- SND Incorporated (Headquarters: Chiyoda-ku, Tokyo; CEO: Takayuki Hiiragi) is proud to announce the launch of its groundbreaking Moderated Drinking Treatment Program for alcohol dependency. This innovative approach offers a compassionate alternative to tradition...

2024-07-23 16:29 1799

Linical Named Best Global CRO by Global Health & Pharma Magazine

OSAKA, Japan, July 23, 2024 /PRNewswire/ -- Linical, a global Contract Research Organization (CRO) for full-service drug development, has been awarded the title ofBest Global CRO 2024 by Global Health & Pharma (GHP) Magazine. The award comes as part of the publication's annual Global Excellence A...

2024-07-23 09:00 2014

DiscGenics Announces US FDA Approval to Proceed with Phase III Clinical Evaluation of Allogeneic, Injectable Disc Progenitor Cell Therapy for Symptomatic Lumbar Degenerative Disc Disease

* Receives FDA acceptance on Phase III clinical protocols for parallel pivotal and confirmatory trials * Achieves alignment with FDA on Chemistry, Manufacturing, and Controls (CMC) aspects of Phase III program SALT LAKE CITY, July 23, 2024 /PRNewswire/ --  DiscGenics, Inc., a privately held, l...

2024-07-23 08:00 1642

QDX Announces Collaboration with Prelude Therapeutics on Novel Oncology Programs

SINGAPORE, July 23, 2024 /PRNewswire/ -- QDX , a computational drug discovery company, today announced a collaboration with Prelude Therapeutics , a clinical-stage precision oncology company, targeting undisclosed, previously undrugged oncology targets....

2024-07-23 08:00 1975

Valinor Pharma Announces Acquisition by Grünenthal with a Total Deal Value of Approximately $250 Million

* Grünenthal acquires Valinor Pharma in an all-stock deal and becomes the owner of the global rights to Movantik® (naloxegol) * Valinor Pharma had owned Movantik since early 2023 and leveraged Apollo Care's commercial platform to grow Movantik volume in the U.S. while reducing gross-to-net a...

2024-07-23 01:23 2220

Momcozy Launches Global Campaign to Support Diverse Breastfeeding Journeys This August

NEW YORK, July 22, 2024 /PRNewswire/ -- Global one-stop mother and baby brand Momcozy  is launching its"Breaking Barriers - Real Support for Breastfeeding Journeys" campaign

2024-07-22 22:00 1622

Lunit's AI Solution Enhances Qatar's National Breast Cancer Screening Program

* Middle East's first full-scale AI adoption for national screening marks Lunit's latest milestone amid rapid expansion of global cancer screening initiatives SEOUL, South Korea, July 22, 2024 /PRNewswire/ -- Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeut...

2024-07-22 21:00 2261

Nature Study Reveals: AI and Molecular Dynamics Designed BGM0504 Exhibits Superior Potency

SHANGHAI, July 22, 2024 /PRNewswire/ -- The molecular design strategy and experimental results of Bright Gene's dual GLP-1/GIP receptor agonist, BGM0504, have been published online in Scientific Reports, a sub-journal of Nature, on July 19, 2024. Bright Gene (Stock Code: 688166.SH) is an innovativ...

2024-07-22 19:48 2506

AmpleLogic Turns 15; Marked in an Evening Filled with Celebrations and Inspiration

HYDERABAD, India, July 22, 2024 /PRNewswire/ -- AmpleLogic, a leader in providingGAMP (Good Automated Manufacturing Practices) solutions , celebrated its 15th anniversary with a grand event onJuly 19, 2024, at Sandhya Convention, Hyderabad. The evening was...

2024-07-22 19:09 2119

Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

* Obese and overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and -17.78%, respectively, with the placebo group at -0...

2024-07-22 19:00 2382

Join Hands for a Brighter Future!2024 Tianjin Binhai New Area Innovation and Entrepreneurship Competition Overseas Event (Hong Kong SAR Division) Concluded Successfully

HONG KONG, July 22, 2024 /PRNewswire/ -- On July 17, 2024, the Hong Kong SAR division of the 2024 Tianjin Binhai New Area Innovation and Entrepreneurship Competition concluded successfully. Top scientists, business leaders, government officials, and elite entrepreneurs from around the world gathe...

2024-07-22 16:41 2047

Hong Kong Seeing Dog Service(HKSEDS)6th Charity Golf Tournament 2024

" Lighting up life with youngsters and elderlies" 2024 HONG KONG, July 22, 2024 /PRNewswire/ -- 10 July 2024(Wed)Hong Kong Seeing Dog Service(HKSEDS)hosted 6th Charity Golf Tournament 2024 at the Hong Kong Golf Club (Fanling) goes smoothly. The purpose of this charity event is to raise funds for...

2024-07-22 11:57 1828

QingSong Health and Globethics Announce Strategic Partnership

BEIJING, July 21, 2024 /PRNewswire/ -- QingSong Health, a leading health technology platform based inChina, has announced a strategic partnership with Globethics,en international leading organization on ethical leadership based in Geneva, Switzerland. This collaboration is set to push forward the...

2024-07-22 11:49 1434

Duke-NUS launches LIVE Ventures, a S$20 million incubator to accelerate research commercialisation

* New incubator aims to tap industry experts to bridge the knowledge and funding gap to enhance bench-to-bedside success * LIVE Ventures provides up to $500,000 for high-potential academic research projects SINGAPORE, July 22, 2024 /PRNewswire/ -- Duke-NUS Medical School today launched LIVE V...

2024-07-22 10:00 2026

Agilent Introduces New ProteoAnalyzer at Singapore Cell and Gene Therapy Pan Asia Summit

SINGAPORE, July 22, 2024 /PRNewswire/ -- Agilent Technologies Inc.  (NYSE: A) today an...

2024-07-22 09:12 2384

Everest Medicines Announces First Chinese Patient Dosed in Global Phase 2b PALIZADE Trial of Zetomipzomib in Lupus Nephritis

SHANGHAI, July 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the first Chinese patient has be...

2024-07-22 09:00 1922

Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA

SAN FRANCISCO and SUZHOU, China, July 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ...

2024-07-22 08:00 3014

Full-Life Technologies Announces the Appointment of Edward (Ted) Myles to Its Board of Directors

HEIDELBERG, Germany and GEMBLOUX, Belgium and SHANGHAI, China, July 21, 2024 /PRNewswire/ -- Full-Life Technologies, a fully integrated global radiotherapeutics company, today announcedthe appointment of Ted Myles to Full-Life's Board of Directors. Mr. Myles will serve as chairman of the audit c...

2024-07-22 08:00 1275

Infinitus Earns Prestigious Mercer China Healthiest Workplace Title and the Outstanding Health Innovation Award

GUANGZHOU, China, July 20, 2024 /PRNewswire/ -- On July 18th, as the 2024-2025 Mercer China Healthiest Workplace List was unveiled, Infinitus received the prestigious "Mercer China Healthiest Workplace" designation and the Outstanding Health Innovation Award.

2024-07-20 03:26 4973
1 ... 53545556575859 ... 858